Skip to main content
CPIX logo

CPIX · Cumberland Pharmaceuticals Inc

Track CPIX — free
$7.09 +0.11 (+1.58%)
Market Cap
$99.34M
Shares
14.98M
Volume · Oct 9 17.21K Avg daily vol (3M) 87.14K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$6.98 Open$6.85 Day$6.31–7.07 52W close$1.90–8.97 Avg vol 30d47K Short int252K · 1.7% float · 8.1d Short vol45% Last earningsAug 4, 2026 DataJan 2020–Oct 2026 Filing10-Q · Aug 7

Up next

Next earnings call
Nov 3, 2026 Est · unconfirmed · in 4 wks
filed Aug 7, 2026
call held Aug 4, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
21.5%
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+90.2%
Trailing year
Short interest
1.7%
Latest settlement · 8.1 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Neutral Momentum Very Strong Sentiment Bullish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 15.4 · calm Equity put/call 0.62
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +31%
above
Price vs 50-day avg −6%
below
RSI (14) 44
neutral
MACD trend Negative
52-week position 72%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +8%
trailing
6-month return +116%
trailing
YTD return +75%
this year
Relative strength +107%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $7 › 200d $5 — 50d above 200d
Institutional flow Accumulating
+10% holders QoQ · +8 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
1.68% of float · ▼ -8.1% MoM · 8.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
33 holders — mid 3-yr range
Squeeze score 53
elevated · 0–100
Fundamentals
Excellent
Revenue growth +17%
Y/Y
EPS growth +59%
Y/Y
Free cash flow $4.8M
Buyback $5.0M
authorized
Quant / Vol
risk profile
Very High
Volatility 87%
annualized · 1-yr
Max drawdown −48%
past year
ATR 7.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+31% Bullish
Price vs 50-day avg
−6% Bearish
RSI (14)
44 Neutral
MACD trend
Negative Bearish
52-week position
72% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $7 › 200d $5 — 50d above 200d
Institutional flow Accumulating
+10% holders QoQ · +8 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
1.68% of float · ▼ -8.1% MoM · 8.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
33 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2 Now $7 · 72% Range high $9
vs 200-day avg +31% vs 50-day avg -6%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CPIX
Cumberland Pharmaceuticals Inc
this stock
$99.34M +75.4% +16.7% — 1.7%
TAK
Takeda Pharmaceutical Co Ltd
$59.16B +18.8% — — 0.1%
GALDY
Galderma Group AG/ADR
$45.83B -5.0% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
$45.74B +25.8% +4.3% 64.3 2.7%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
$41.48B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
33
% held
18.9%
Net QoQ
-85.1K sh
Top holder
Ikarian Capital, LLC
Held Float
View
Held by Funds
Fund positions
30
View
Short & Settlement
Short Interest Falling
Shares short
252.5K
Days to cover
8.1d
Change
-22.2K sh
View
Short Volume
Short vol %
45%
As of
Oct 8, 2026
Short Total
View
Fails to Deliver
FTD shares
4
Value
$31
As of
Aug 25, 2026
View
Off-Exchange
Off-exchange %
43.1%
Week of
Aug 31, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$44.5M
Net income (FY)
$-2.8M
EPS diluted
$-0.19
View
Buybacks
Authorized
$5.0M
View
Filings
SEC Filings
Latest
8-K/A
Filed
Sep 11, 2026
This year
15
View
Earnings & Events
Webcasts
Last webcast
Aug 4, 2026
View

Performance

5D 20D 120D MTD YTD
CPIX -7.1% +7.7% +116.1% -10.9% +75.4%
SPY +1.3% +2.1% +9.0% +1.5% +13.5%
vs SPY -8.4% +5.6% +107.1% -12.3% +61.9%

Capital returns

Latest dividend
$1.50 / share · ex Aug 3, 2026
Paid (TTM)
$1.50 / share · 1 payout
Dividend yield (TTM, derived)
— · history filling in
Buyback program · as of Jul 13, 2026
Authorized
$5.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1087294 CUSIP 230770109 13F (30d) 1 filings 1 filers Visit website Investor relations